# Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer

> **NCT01426880** · PHASE2,PHASE3 · COMPLETED · sponsor: **GBG Forschungs GmbH** · enrollment: 595 (actual)

## Conditions studied

- Tubular Breast Cancer Stage II
- Mucinous Breast Cancer Stage II
- Breast Cancer Female NOS
- Invasive Ductal Breast Cancer
- Tubular Breast Cancer Stage III
- HER-2 Positive Breast Cancer
- Inflammatory Breast Cancer Stage IV
- Inflammatory Breast Cancer

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** background treatment

## Key facts

- **NCT ID:** NCT01426880
- **Lead sponsor:** GBG Forschungs GmbH
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08
- **Primary completion:** 2013-05
- **Final completion:** 2013-08
- **Target enrollment:** 595 (ACTUAL)
- **Last updated:** 2016-02-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01426880

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01426880, "Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01426880. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*